The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients

Oncol Lett
07 June 2022
https://pubmed.ncbi.nlm.nih.gov/35761946/

Tim - England: Eye cancer (2022) (LDN; low dose naltrexone)

Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

Curr Oncol Rep
01 June 2022
https://pubmed.ncbi.nlm.nih.gov/35648340/

LDN Webinar Presentation 18 May 2022: Dr Mathewson - LDN as supportive care for Oncology and Autoimmune patients: Case Reviews

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar Presentation 18 May 2022: Dr Sato-Re - How and why I prescribe LDN in my integrative and general practice

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar 18 May 2022 (LDN; low dose naltrexone)

LDN Questions Answered Live by

Pharmacist Dr Masoud Rashidi - LDN Specialist
Dr Sato-Re
Dr Mathewson

Sponsored by Innovative Compounding Pharmacy icpfolsom.com

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

GlobalNewswire
27 April 2022
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html

Yusuf (JP) Saleeby, MD - LDN to help Long Covid patients; March 2022 (LDN, low dose naltrexone)